1. Clinical Overview
L-Ornithine L-Aspartate (LOLA) is a stable salt of two amino acids, L-Ornithine and L-Aspartate. It is a key hepatoprotective and detoxifying agent primarily used in the management of hepatic encephalopathy (HE) and hyperammonemia. It works by enhancing the urea cycle and glutamine synthesis in the liver and skeletal muscle, facilitating the detoxification and excretion of ammonia. In the Indian market, it is widely prescribed for acute and chronic liver diseases, including cirrhosis and alcohol-related liver damage.
| Onset | Duration | Bioavailability |
|---|---|---|
| Within 1-2 hours for plasma ammonia reduction. | Approximately 6-8 hours, necessitating multiple daily doses. | Oral bioavailability is low and variable (<10%) due to significant first-pass metabolism. Intravenous administration provides 100% bioavailability. |
2. Mechanism of Action
L-Ornithine L-Aspartate provides substrates for two major pathways of ammonia detoxification: 1) The Urea Cycle in periportal hepatocytes: L-Ornithine is a direct substrate, activating ornithine transcarbamylase and carbamoyl phosphate synthetase, enhancing urea synthesis. 2) The Glutamine Synthesis Pathway in perivenous hepatocytes and skeletal muscle: L-Aspartate, along with glutamate, provides substrate for glutamine synthetase, which traps ammonia as glutamine. This dual mechanism effectively lowers circulating ammonia levels.
3. Indications & Uses
- Treatment and prevention of Hepatic Encephalopathy (acute and chronic)
- Management of hyperammonemia in chronic liver disease (cirrhosis)
4. Dosage & Administration
Adult Dosage: Oral: 3-6 grams (commonly 1-2 sachets of 3g each) three times daily, dissolved in water/juice. Intravenous: 10-20 grams per day, infused slowly in 500 mL of IV fluid over 4-6 hours. Maximum IV dose: 40 grams/day in severe cases.
Administration: Oral Granules/Sachets: Dissolve the entire content of the sachet in a glass of water or non-acidic fruit juice (approx. 150-200 mL) and consume immediately. Take after meals to improve GI tolerance. IV Infusion: Must be diluted in 500 mL of compatible IV fluid (e.g., 5% Dextrose, Normal Saline, Ringer's Lactate). Administer as a slow infusion over 4-6 hours to avoid nausea and vomiting. Do not administer as a bolus injection.
5. Side Effects
Common side effects may include:
- Nausea
- Vomiting (especially with rapid IV infusion)
- Gastrointestinal discomfort
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Potassium-Sparing Diuretics (e.g., Spironolactone) | Increased risk of severe hyperkalemia due to additive effects. | Major |
| Potassium Supplements / Salt Substitutes | Increased risk of hyperkalemia. | Major |
| ACE Inhibitors (e.g., Ramipril) / ARBs (e.g., Telmisartan) | Increased risk of hyperkalemia. | Moderate |
| Corticosteroids | May counteract potassium-lowering effect, monitor electrolytes. | Moderate |
| Lactulose | Additive/synergistic effect in lowering ammonia. Commonly used together in hepatic encephalopathy. | Minor (Beneficial) |
7. Patient Counselling
- DO take the medication exactly as prescribed, especially with meals if oral.
- DO dissolve the entire oral sachet in a full glass of water or juice.
- DO inform all your doctors about your liver condition and this medication.
- DONT stop taking the medication suddenly without consulting your doctor.
- DONT take any other medications, including OTC painkillers (like NSAIDs), without asking your doctor.
- DONT consume alcohol in any form.
8. Toxicology & Storage
Overdose: Symptoms are primarily extensions of side effects: severe nausea, vomiting, diarrhea, metabolic alkalosis, and hyperkalemia (leading to cardiac arrhythmias, muscle weakness).
Storage: Store in a cool, dry place, protected from light and moisture. Keep oral sachets in their original packaging until use. Keep out of reach of children. Do not use after the expiry date printed on the pack. Reconstituted oral solution should be consumed immediately. IV solutions should be used immediately after preparation; discard any unused portion.